REDWOOD CITY, Calif., Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-andanswer) session at the Wells Fargo 2024 Healthcare Conference on Friday, September 6, 2024, beginning at 8:45 a.m. EDT. A live webcast of the session and a replay of the webcast will be available on the Eve ...

Justin Paget Shares of Nevro Corp. (NYSE:NVRO) have fallen to fresh lows after the company reset the guidance for the year. This did not really come as a complete surprise to me after I concluded that the company was causing back pains for investors in February of last year. After multiple boom-bust cycles for the shares in the past, shares arrived at a bust phase again. Unlike previous episodes, I believe that the growth story has been impaired after revenues have been stagnant for a while. While the resul ...

Nevro Corp. (NVRO) reported a loss per share of 53 cents in the second quarter of 2024, narrower than the year-ago quarter's loss of 69 cents. The metric beat the Zacks Consensus Estimate of a loss per share of 63 cents. Revenues in Detail Nevro registered worldwide revenues of $104.2 million in the second quarter, down 4.3% year over year on a reported basis and 4.2% on a constant-currency basis. The year-over-year decline was primarily due to the result of competitive pressures in the U.S. spinal cord sti ...

Nevro (NVRO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 31.75%. A quarter ago, it was expected that this maker of an electrical implant that treats leg and back pain would post a loss of $1.02 per share when it actually produced a loss of $0.70, delivering a surprise of 31.37%. Over the ...

IIIIIIII neving Second-Quarter 2024 Earnings Conference Call August 6, 2024 ©2024 Nevro Corp. All rights reserved. S000000 Forward-Looking Statements In addition to historical information, this presentation contains forward-looking statements reflecting the current beliefs and expectations of the company's management, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our revised full-year 2024 financial guidance and our third quarter 2024 financi ...

Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif., Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, toda ...

REDWOOD CITY, Calif., July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. For those parties that do not have internet access, th ...

Company Overview - Nevro Corp. is a global medical device company headquartered in Redwood City, California, focused on chronic pain treatment solutions [1] - The company has developed the proprietary 10 kHz Therapy™, which has positively impacted over 115,000 patients worldwide [1] Product Offerings - Nevro's HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and services for treating chronic pain and painful diabetic neuropathy [1] - The company recently introduced a minimally invasive treatment option for chronic sacroiliac joint pain, expanding its product portfolio in the SI joint fusion space [9] Investor Engagement - Nevro's management team will participate in a "fireside chat" at the Truist Securities MedTech Conference on June 18, 2024, at approximately 8:40 am EDT [7] - The company encourages investors to regularly check its website for important updates and information [8]

It has been about a month since the last earnings report for Nevro (NVRO) . Shares have lost about 8.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Nevro due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Nevro's Q1 Earnings and Sales Top Estimates, Margins Up ...

Core Viewpoint - Nevro Corp. is positioned for growth due to its R&D capabilities and strong performance in Q1 2024, despite facing competition and reliance on third-party payors [1][2]. Company Performance - Nevro has a market capitalization of $343.4 million and projects a growth rate of 13.8% for 2024, with earnings surpassing estimates in three of the last four quarters, averaging a surprise of 28.87% [2]. - The company reported better-than-expected results in Q1 2024, with robust domestic revenues and an increase in U.S. permanent implant procedures [9]. Product Development and R&D - Nevro is enhancing its Senza platform and developing new indications to improve patient outcomes and expand access to HF10 therapy [3]. - The HFX iQ system accounted for 58% of permanent implant procedures in Q1 2024, indicating strong adoption [4]. - The acquisition of Vyrsa allows Nevro to enter the SI joint fusion market, expected to generate additional revenues in H2 2024 [5]. Clinical Evidence - Data from the SENZA-PDN RCT showed improvements in sensory function for diabetes patients, potentially reducing ulceration and amputation risks [7]. - The SENZA NSRBP trial published 24-month data demonstrating significant improvements in pain, function, and quality of life for patients using high-frequency SCS [8]. Market Challenges - Nevro's success is contingent on third-party payors providing adequate coverage for its products, which is critical for consumer acceptance [11]. - The company faces stiff competition in the medical device industry, necessitating a strong consumer approval for its therapies [12]. Estimate Trends - There has been a negative estimate revision trend for 2024, with the loss estimate narrowing from $2.54 to $2.12 per share in the last 30 days [13]. - The Zacks Consensus Estimate for Q2 2024 revenues is $107.1 million, reflecting a 1.6% decline from the previous year [13].